Equities

Fibrobiologics Inc

Fibrobiologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.30
  • Today's Change0.14 / 4.43%
  • Shares traded2.00m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

  • Revenue in USD (TTM)0.00
  • Net income in USD-19.47m
  • Incorporated2021
  • Employees10.00
  • Location
    Fibrobiologics Inc455 E. Medical Center Blvd, Suite 300HOUSTON 77598United StatesUSA
  • Phone+1 (281) 671-5150
  • Fax+1 (302) 655-5049
  • Websitehttps://fibrobiologics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Checkpoint Therapeutics Inc78.00k-42.47m108.49m23.00------1,390.94-1.50-1.500.0027-0.3720.0111--2.173,391.30-606.33-142.43---342.79-----54,444.87-6,554.97---------46.35-50.6117.21------
ALX Oncology Holdings Inc0.00-171.44m109.03m74.00--0.6815-----3.64-3.640.003.040.00----0.00-74.45-34.34-84.76-36.47-------7,238.76----0.0734-------30.23--14.30--
Annovis Bio Inc0.00-43.02m110.57m6.00---------4.42-4.420.00-0.14940.00----0.00-308.78-106.31-395.89-124.71-----------51.53---------121.90------
Anixa Biosciences Inc0.00-12.36m111.98m4.00--5.14-----0.3906-0.39060.000.67720.00----0.00-50.54-59.69-52.50-62.61-------6,040.10----0.00-----28.3627.83------
Citius Oncology Inc0.001.93m114.09m--6.610.230959.00--0.2420.2420.006.930.00------3.25--3.35--------------0.036------535.30------
INmune Bio Inc85.00k-37.74m115.74m11.00--2.77--1,361.65-2.06-2.060.00461.880.0014--0.03117,727.27-61.78-37.82-80.24-41.86-----44,402.35-14,901.03---23.010.1184---58.56---9.92------
Verastem Inc10.00m-89.49m115.90m73.00--4.11--11.59-3.34-3.340.37261.490.0672--2.00136,986.30-60.16-62.70-72.65-75.18-----894.91-406.17----0.5052---100.00---18.36------
Fibrobiologics Inc0.00-19.47m116.03m10.00---------0.939-0.9390.00-0.0730.00----0.00-171.13---333.35-----------------------272.15------
Coherus Biosciences Inc308.13m-29.34m117.51m246.00------0.3814-0.4014-0.40142.74-0.73010.53852.861.951,006,974.00-5.13-21.43-11.46-29.3241.5179.01-9.52-36.561.07-4.021.47--21.89--18.46---18.37--
PDS Biotechnology Corp0.00-40.68m117.82m25.00--3.81-----1.23-1.230.000.84060.00----0.00-65.48-51.63-80.82-59.00-----------21.590.4409-------5.11------
X4 Pharmaceuticals Inc563.00k17.63m119.13m93.008.251.266.60211.600.08570.08570.00280.56160.0029--0.67266,053.769.18-61.5310.59-69.2052.40--3,131.79-13,288.936.04--0.4427-------4.93--12.03--
Regulus Therapeutics Inc0.00-35.39m119.15m31.00--1.21-----1.26-1.260.001.500.00----0.00-47.90-53.74-52.71-76.96-------715.58----0.00-------6.05--94.54--
Nuvectis Pharma Inc0.00-21.10m121.24m13.00--9.73-----1.29-1.290.000.66820.00----0.00-97.61---128.44--------------0.00-------16.64------
Assembly Biosciences Inc21.48m-45.61m123.29m65.00--3.55--5.74-9.32-9.324.285.470.2362--125.62330,476.90-50.15-39.69-69.22-44.03-----212.33-409.24----0.00-----13.5134.23---5.59--
Cardiff Oncology Inc665.00k-40.88m124.75m31.00--2.33--187.60-0.9142-0.91420.01491.150.0081--2.1721,451.61-49.98-31.24-57.60-33.56-----6,143.91-7,819.23----0.00--26.425.22-7.07--157.91--
Rani Therapeutics Holdings Inc0.00-30.58m124.97m140.00--41.77-----1.18-1.180.000.0560.00----0.00-95.14---154.95-------------21.580.8416-------11.06------
Data as of Sep 20 2024. Currency figures normalised to Fibrobiologics Inc's reporting currency: US Dollar USD

Institutional shareholders

7.01%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 2024824.61k2.35%
SSgA Funds Management, Inc.as of 30 Jun 2024376.05k1.07%
Geode Capital Management LLCas of 30 Jun 2024315.71k0.90%
Cascade Financial Partners LLCas of 30 Jun 2024315.06k0.90%
The Vanguard Group, Inc.as of 30 Jun 2024180.05k0.51%
Transform Wealth LLCas of 30 Jun 2024133.89k0.38%
Requisite Capital Management LLCas of 30 Jun 2024109.71k0.31%
American Institute for Advanced Investment Management LLPas of 30 Jun 202488.21k0.25%
Charles Schwab Investment Management, Inc.as of 30 Jun 202466.28k0.19%
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 202456.08k0.16%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.